Rovatinex usage in pediatric urology

One of the main precursors of the inflammation in kidneys are the pathological changes in urodynamics. These changes are a consequence of the urogenital (congenital) anomalies: ureteral orifice dysplasia, ureteral stricture, vesico-ureteral reflux and primary megaureter, congenital hydronephrosis and infravesical obstruction, neurogenic bladder dysfunction. Rovatinex shows a complex activity, which obviates its use in clinical practice. It potentiates antibiotic activity of different substances, showing also a nephroprotective and antioxidant actions. Rovatinex is to use as a combination with antibiotics in an active phase and to prevent the recurrence later on using the 3-months intake courses without cessation, when there is no evidence of the acute recurrence. The aim of this study was to evaluate the efficacy of Rovatinex in 6-11 years old children, which have a most prominent susceptibility to the urinary tract infections. The treatment with the addition of Rovatinex was used in children with a background of the pyelo-ureteral junction obstruction, stricture of the pelvic ureter and primary megaureter, which also underwent the ‘programmed’ stenting. As the result of the study it could be concluded that Rovatinex in children on the ‘programmed’ stenting was able to prevent the stent incrustation, decrease leucocyturia, eliminate bacteriuria and oxaluria. Rovatinex intake was not a cause of the serious side effects in this group of the patients.